Phase II Clinical Development of New Drugs

Name: Phase II Clinical Development of New Drugs
Author: Naitee Ting, Joseph C. Cappelleri, Shuyen Ho, Ding-Geng Chen
ISBN: 9789811041921

Naitee Ting, Joseph C. Cappelleri, Shuyen Ho, Ding-Geng Chen

Language: English

Published by Springer Nature Singapore, 2017

981104192X / 9789811041921

Series: Book 9 of 19 - ICSA Book Series in Statistics

Hardcover
Used

See all details

Seller: Buchpark, Trebbin, GermanyBuchpark

5-star seller

AbeBooks seller since September 30, 2021

View this seller's items

Hardcover

Condition: Used - Very good

US$ 85.87

US$ 120.42 shipping

Ships from Germany to U.S.A.

Quantity: 1 available

Add to basket

Free 30-day returns

Save for laterCreate a Want for similar items

Item description from seller

Zustand: Gut | Seiten: 260 | Sprache: Englisch | Produktart: Bücher | This book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it warns project team members of the common potential pitfalls and offers tips on how to avoid them.

Seller Inventory # 28419251/3

Contact seller about this item

Report this item

Title: Phase II Clinical Development of New Drugs
Author: Naitee Ting, Joseph C. Cappelleri, Shuyen Ho, Ding-Geng Chen
Publisher: Springer Nature Singapore
Publication year: 2017
Condition: Gut
Binding: Hardcover
Language: English
ISBN 10: 981104192X
ISBN 13: 9789811041921
Series: Book 9 of 19: ICSA Book Series in Statistics
Seller catalogs: Bücher

About the Author

Naitee Ting is a Fellow of ASA. He is currently a Director in the Department of Biostatistics and Data Sciences at Boehringer-Ingelheim Pharmaceuticals Inc. (BI). He joined BI in September of 2009, and before joining BI, he was at Pfizer Inc. for 22 years (1987-2009). Naitee received his Ph.D. in 1987 from Colorado State University (major in Statistics). He has an M.S. degree from Mississippi State University (1979, Statistics) and a B.S. degree from College of Chinese Culture (1976, Forestry) at Taipei, Taiwan.

Naitee published articles in Technometrics, Statistics in Medicine, Drug Information Journal, Journal of Statistical Planning and Inference, Journal of Biopharmaceutical Statistics, Biometrical Journal, Statistics and Probability Letters, and Journal of Statistical Computation and Simulation. His book "Dose Finding in Drug Development" was published in 2006 by Springer, and is considered as the leading reference in the field ofdose response clinical trials. The book "Fundamental Concepts for New Clinical Trialists", co-authored with Scott Evans, was published by CRC in 2015. Naitee is an adjunct professor of Columbia University, University of Connecticut and University of Rhode Island. Naitee has been an active member of both the American Statistical Association (ASA) and the International Chinese Statistical Association (ICSA).

Professor Ding-Geng Chen is a fellow of the American Statistical Association and currently the Wallace Kuralt distinguished professor at the University of North Carolina at Chapel Hill, USA, and an extraordinary professor at University of Pretoria, South Africa. He was a professor at the University of Rochester and the Karl E. Peace endowed eminent scholar chair in biostatistics at Georgia Southern University. He is also a senior consultant for biopharmaceuticals and government agencies with extensive expertise in clinical trial biostatistics and public health statistics. Professor Chen has written more than 150 referred publications and co-authored/co-edited twelve books on clinical trial methodology with R and SAS, meta-analysis using R, advanced statistical causal-inference modeling, Monte-Carlo simulations, advanced public health statistics and statistical models in data science.

Shuyen Ho received his PhD in Statistics from University of Wisconsin – Madison, and his Bachelor in Applied Mathematics from Taiwan. Dr. Ho is a Biostatistics Director at PAREXEL International in Durham, North Carolina and has worked in the pharmaceutical industry for over 25 years. Prior to PAREXEL, he was a Clinical Statistics Director at GlaxoSmithKline (GSK) and Group Leader at Merck. He specializes in Phase II & III clinical development and has helped developed widely used respiratory medicines such as Claritin, Advair and Veramyst.

Joseph C. Cappelleri earned his MS in statistics from the City University of New York (Baruch College), PhD in psychometrics from Cornell University, and MPH in epidemiology from Harvard University. Dr. Cappelleri is a senior director of biostatistics at Pfizer Inc. He has also served on the adjunct faculties at Brown University, Tufts Medical Center, and the University of Connecticut. A Fellow of the American Statistical Association, he has delivered numerous conference presentations and published extensively on clinical and methodological topics, including regression-discontinuity designs, meta-analysis, and health measurement scales. Dr. Cappelleri is the lead author of the book “Patient-Reported Outcomes: Measurement, Implementation and Interpretation.”

"About the title" may belong to another edition of this title.

Buchpark

Trebbin, Germany

5-star seller

AbeBooks seller since September 30, 2021

Shipping rates from Germany to U.S.A.

Item	60 to 60 business days	60 to 60 business days
First item	US$ 120.42	US$ 149.09

Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.

Payment methods

Bank Wire Transfer
Check
Paypal

Store description

Seit über 30 Jahren handeln wir mit Büchern. Begonnen hat alles als kleiner Fachbuchhandel in Berlin. Heute sind wir spezialisiert auf den An- und Verkauf gebrauchter Bücher. Noch immer liegt unser Fokus dabei auf den Kategorien: Fachbuch und englischsprachige Literatur. Hinzu kommen Bücher aus allen anderen Genres, wie Belletristik, Biografien oder Kinderbücher. Unser oberstes Ziel ist dabei die Weiterverwendung von Dingen und die Schonung von Ressourcen. Neben dem Ankauf von privaten Büchern oder Haushaltsauflösungen kaufen wir bundesweit komplette Bibliotheken und Buchbestände von Institutionen auf, um diese nachhaltig ein weiteres Mal auf den Markt zu bringen. Parallel dazu bietet Buchpark die Möglichkeit, große Mengen einzulagern. Ganze Bibliotheken und umfangreiche Buchbestände werden von uns professionell auf Qualitätsmerkmale hin untersucht und sorgfältig für den Onlinehandel aufbereitet. Wir schenken Büchern ein zweites Leben.…

Seller's business information

Buchpark GmbH

Krügerweg 1
Trebbin, Germany 14959

Contact sellerView this seller's itemsView seller's storefront

Phase II Clinical Development of New Drugs

Item description from seller

Bibliographic details

Synopsis

About the title